Prestige BioPharma Limited (KRX:950210)

Prestige BioPharma Revenue

In the fiscal year ending June 30, 2026, Prestige BioPharma had annual revenue of 26.07B KRW with 81.99% growth. Prestige BioPharma had revenue of 15.39B in the quarter ending June 30, 2026, with 178.46% growth. That makes Prestige BioPharma the 33,959th largest company in the world by revenue and 2,169th in South Korea.

• Revenue: 26.07B
• Revenue Growth: +81.99%
• P/S Ratio: 2.60
• Revenue / Employee: 407.37M
• Employees: 64
• Market Cap: 67.79B

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	26.07B	11.75B	81.99%
Jun 30, 2025	14.33B	13.64B	1,978.97%
Jun 30, 2024	689.08M	527.23M	325.77%
Jun 30, 2023	161.84M	-	-
Jun 30, 2022	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Sep 21, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 10, 2026

Data Sources Report a data error